Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up
Abstract Introduction Autoimmune pulmonary alveolar proteinosis (aPAP) is a disease caused by IgG antibodies against granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). Whole lung lavage (WLL) allows to remove the lipo‐proteinaceous material accumulated by the poor clearance of alveolar surfa...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-10-01
|
| Series: | The Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/crj.13650 |
| _version_ | 1797668925881712640 |
|---|---|
| author | Iván Oterino‐Moreira María‐Jesús Linares‐Asensio Sira Sanz‐Márquez Montserrat Pérez‐Encinas |
| author_facet | Iván Oterino‐Moreira María‐Jesús Linares‐Asensio Sira Sanz‐Márquez Montserrat Pérez‐Encinas |
| author_sort | Iván Oterino‐Moreira |
| collection | DOAJ |
| description | Abstract Introduction Autoimmune pulmonary alveolar proteinosis (aPAP) is a disease caused by IgG antibodies against granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). Whole lung lavage (WLL) allows to remove the lipo‐proteinaceous material accumulated by the poor clearance of alveolar surfactant. However, it is a complex technique that is not exempt from complications, and in some cases, the patients are refractory, requiring the performance of several WLLs spaced apart in time. Materials and Methods We present the clinical, functional, and radiological evolution after 24 months of follow‐up of a patient diagnosis of aPAP refractory to WLL, with performed three therapeutic WLLs spaced 16 and 36 months and serious potentially fatal complications in the last one. Results and Disscusion After 24 months, no adverse effects have appeared and the great clinical, functional and radiological response is maintained. The patient has been successfully treated with inhaled recombinant human GM‐CSF sargramostim. |
| first_indexed | 2024-03-11T20:36:38Z |
| format | Article |
| id | doaj.art-c0856f6c3e284b949386edf93b0891c3 |
| institution | Directory Open Access Journal |
| issn | 1752-6981 1752-699X |
| language | English |
| last_indexed | 2024-03-11T20:36:38Z |
| publishDate | 2023-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Clinical Respiratory Journal |
| spelling | doaj.art-c0856f6c3e284b949386edf93b0891c32023-10-02T06:33:21ZengWileyThe Clinical Respiratory Journal1752-69811752-699X2023-10-0117101077108110.1111/crj.13650Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐upIván Oterino‐Moreira0María‐Jesús Linares‐Asensio1Sira Sanz‐Márquez2Montserrat Pérez‐Encinas3Pharmacy Department Alcorcon Foundation University Hospital Alcorcon SpainPulmonology Department Alcorcon Foundation University Hospital Alcorcon SpainPharmacy Department Alcorcon Foundation University Hospital Alcorcon SpainPharmacy Department Alcorcon Foundation University Hospital Alcorcon SpainAbstract Introduction Autoimmune pulmonary alveolar proteinosis (aPAP) is a disease caused by IgG antibodies against granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). Whole lung lavage (WLL) allows to remove the lipo‐proteinaceous material accumulated by the poor clearance of alveolar surfactant. However, it is a complex technique that is not exempt from complications, and in some cases, the patients are refractory, requiring the performance of several WLLs spaced apart in time. Materials and Methods We present the clinical, functional, and radiological evolution after 24 months of follow‐up of a patient diagnosis of aPAP refractory to WLL, with performed three therapeutic WLLs spaced 16 and 36 months and serious potentially fatal complications in the last one. Results and Disscusion After 24 months, no adverse effects have appeared and the great clinical, functional and radiological response is maintained. The patient has been successfully treated with inhaled recombinant human GM‐CSF sargramostim.https://doi.org/10.1111/crj.13650aerosol drug therapygranulocyte‐macrophage colony‐stimulating factorinhalation drug administrationpulmonary alveolar proteinosissargramostim |
| spellingShingle | Iván Oterino‐Moreira María‐Jesús Linares‐Asensio Sira Sanz‐Márquez Montserrat Pérez‐Encinas Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up The Clinical Respiratory Journal aerosol drug therapy granulocyte‐macrophage colony‐stimulating factor inhalation drug administration pulmonary alveolar proteinosis sargramostim |
| title | Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
| title_full | Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
| title_fullStr | Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
| title_full_unstemmed | Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
| title_short | Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
| title_sort | response to inhaled granulocyte macrophage colony stimulating factor in patient with mild to moderate autoimmune pulmonary alveolar proteinosis 24 months of follow up |
| topic | aerosol drug therapy granulocyte‐macrophage colony‐stimulating factor inhalation drug administration pulmonary alveolar proteinosis sargramostim |
| url | https://doi.org/10.1111/crj.13650 |
| work_keys_str_mv | AT ivanoterinomoreira responsetoinhaledgranulocytemacrophagecolonystimulatingfactorinpatientwithmildtomoderateautoimmunepulmonaryalveolarproteinosis24monthsoffollowup AT mariajesuslinaresasensio responsetoinhaledgranulocytemacrophagecolonystimulatingfactorinpatientwithmildtomoderateautoimmunepulmonaryalveolarproteinosis24monthsoffollowup AT sirasanzmarquez responsetoinhaledgranulocytemacrophagecolonystimulatingfactorinpatientwithmildtomoderateautoimmunepulmonaryalveolarproteinosis24monthsoffollowup AT montserratperezencinas responsetoinhaledgranulocytemacrophagecolonystimulatingfactorinpatientwithmildtomoderateautoimmunepulmonaryalveolarproteinosis24monthsoffollowup |